Basilea Pharmaceutica Balance Sheet Health
Financial Health criteria checks 6/6
Basilea Pharmaceutica has a total shareholder equity of CHF103.2M and total debt of CHF82.0M, which brings its debt-to-equity ratio to 79.5%. Its total assets and total liabilities are CHF248.8M and CHF145.7M respectively. Basilea Pharmaceutica's EBIT is CHF76.6M making its interest coverage ratio 31.9. It has cash and short-term investments of CHF128.4M.
Key information
79.47%
Debt to equity ratio
CHF 81.98m
Debt
| Interest coverage ratio | 31.9x |
| Cash | CHF 128.37m |
| Equity | CHF 103.16m |
| Total liabilities | CHF 145.69m |
| Total assets | CHF 248.85m |
Recent financial health updates
Recent updates
Basilea Pharmaceutica (VTX:BSLN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Aug 29
Emerging Markets And Drug Resistance Will Drive Global Expansion
Key Takeaways Expanding global sales of key anti-infective drugs and successful commercialization partnerships are driving top-line growth and increased royalty income. Strategic pipeline development, acquisitions, and a partnership-driven model support profit growth, regulatory momentum, and future market expansion.Benign Growth For Basilea Pharmaceutica AG (VTX:BSLN) Underpins Its Share Price
Jul 29Shareholders Will Probably Hold Off On Increasing Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For The Time Being
Apr 10Estimating The Intrinsic Value Of Basilea Pharmaceutica AG (VTX:BSLN)
Apr 04There May Be Underlying Issues With The Quality Of Basilea Pharmaceutica's (VTX:BSLN) Earnings
Feb 26Basilea Pharmaceutica (VTX:BSLN) Could Easily Take On More Debt
Feb 20Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now
Apr 18Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?
Sep 20Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)
Feb 17Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)
Jul 01Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long
Mar 24If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%
Feb 18Financial Position Analysis
Short Term Liabilities: BSLN's short term assets (CHF217.5M) exceed its short term liabilities (CHF34.4M).
Long Term Liabilities: BSLN's short term assets (CHF217.5M) exceed its long term liabilities (CHF111.3M).
Debt to Equity History and Analysis
Debt Level: BSLN has more cash than its total debt.
Reducing Debt: BSLN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: BSLN's debt is well covered by operating cash flow (97%).
Interest Coverage: BSLN's interest payments on its debt are well covered by EBIT (31.9x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/15 17:22 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Basilea Pharmaceutica AG is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Markus Mayer | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |